相关实验视频
Updated: Jan 14, 2026

08:05
Murine Model of Allergen Induced Asthma
Published on: May 14, 2012
41.2K
在吸入过敏原挑战期间伊塔科纳酸的保护作用
Gesa J Albers1, Patricia P Ogger1, Christina Michalaki1
1National Heart and Lung Institute, Imperial College London, London, UK.
Allergy
|October 25, 2025
概括
在轻度喘中暴露于过敏原后,伊塔科纳酸的水平会下降. 虽然伊塔科纳酸缺乏对小鼠的喘病理没有影响,但吸入的伊塔科纳酸减少了呼吸道炎症,这表明它对喘有治疗潜力.
科学领域:
- 免疫学 免疫学 免疫学
- 代谢学 代谢学 代谢学
- 呼吸系统医学 呼吸系统医学
背景情况:
- 喘是一种慢性呼吸道疾病,涉及呼吸道炎症和重塑.
- 在喘中至关重要的巨细胞功能受到细胞代谢的调节,包括TCA循环代谢物伊塔康酸.
- 在喘中吸入过敏原挑战期间,伊塔科尼酸的作用尚不清楚.
研究的目的:
- 调查伊塔科纳酸在呼吸过敏原挑战喘中的作用.
- 确定在轻度过敏性喘患者和小鼠模型中暴露过敏原后,伊塔科纳酸水平如何变化.
主要方法:
- 测量了人类参与者和野生类型/阿基尼酶脱碳酶缺乏的小鼠的唾液和支气管洗代谢物水平.
- 评估了小鼠的呼吸道炎症和肺功能.
- 用于吸入的伊塔科纳酸,用于室内暴露于灰尘虫的小鼠.
主要成果:
- 在轻度喘患者吸入过敏原后,液中伊塔科纳酸盐水平显著下降.
- 在健康对照组和不同严重程度的喘患者之间没有观察到基线唾液伊塔康酸的显著差异.
- 在小鼠中,伊塔科纳酸缺乏并没有改变过敏原诱导的喘病理,但吸入的伊塔科纳酸治疗减少了呼吸道炎症.
结论:
- 在轻度喘患者和小鼠模型中,在过敏原挑战后,伊塔科纳酸的水平发生动态变化.
- 虽然伊塔科纳特缺乏本身并没有加剧小鼠的喘病理,但外源性伊塔科纳特显示出抗炎作用.
- 吸入的伊塔科纳酸具有作为治疗剂的潜力,可以改善过敏性喘中的炎症反应.
相关概念视频
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
1.5K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.5K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
Allergic Reactions
32.0K
Overview
32.0K
Asthma-I: Introduction
3.4K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
3.4K
Asthma-IV: Nursing Management
3.7K
The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
First, in...
3.7K
Antiasthma Drugs: Muscarinic Receptor Antagonists
1.7K
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
1.7K

